Development of analgesic effective PLGA nanoparticles; Evaluation of in vitro release kinetic and cytotoxicity profile

Yazan E. Y., Akyıl E., Öztürk A. A. (Executive), Şenel B., Martin Banderas L., Cayero Otero M. D.

Project Supported by Higher Education Institutions, 2017 - 2019

  • Project Type: Project Supported by Higher Education Institutions
  • Begin Date: November 2017
  • End Date: May 2019

Project Abstract

Pain is defined as an unpleasant sensation involving all the experiences of a person's past life, which can arise from any part of the body in human metabolism, with or without organic gnawing. In medical literature, pain is mainly studied under two groups. Among these, acute pain emerges as a newborn of different diseases and the other is chronic pain. Acute pain, which is one of the most important parts of the body's alarm system, is often a reporter of tissue damage present in the body or a symptom of an illness. Chronic pain is a type of pain that lasts for 3-6 months and lasts longer than being an alarm system. Chronic pain is not a disease narrator, but the problem itself. Both acute and chronic pain; there are social and economic losses within the treatment range. he use of pain medication in modern treatment has an important place in treatment. Today, in the treatment of the drug, the patient is exposed several times a day and in large doses. High doses have serious side effects with it. Dexketoprofen trometamol; is an analgesic, antiinflammatory and antipyretic drug active agent in the non-steroidal antiinflammatory drug (NSAID) group. The short half-life active dexketoprofen trometamol is administered to the patient three times a day. Three doses may increase toxic effects as well as disrupt patient comfort and cause problems such as forgetting dosing. The polymeric nanoparticulate system is a drug-delivery system that has been intensively studied over the last few years, providing controlled and sustained release. In this study; DT loaded polymeric nanoparticle system will be prepared to prolong release of active substance by the method of nanoprecipitation using PLGA (Poly Lactic-co-Glycolic Acid) polymer. Scope of work; Development of formulations, in vitro characterization, short-term stability study to be performed in gastrointestinal fluids, and determination of the cytotoxic profile of the optimal formulation selected. It is thought that the prepared formulations will create a new approach in pain treatment. The specificity of this study implies that no nano-carrier system with dexketoprofen trometamol loaded with PLGA (Poly Lactic-co-glycolic acid) base is developed until now and treatment with longer-term treatment with low-dose dexketoprofen trometamol.